A longitudinal VBM study monitoring treatment with erythropoietin in patients with Friedreich ataxia
{{output}}
Background: Recombinant human erythropoietin (rhuEPO) has received considerable attention because of its neuroprotective properties. It has recently been reported that rhuEPO increases frataxin levels in combination with clinical... ...
